CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 48 enrolled
Drug / intervention
Metformin +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00108615
NCT00108615Phase 4Completed
CompareCT.gov

Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance

US Department of Veterans Affairs·interventional·Posted Apr 18, 2005·Updated Apr 25, 2008

In Brief

A Phase 4 clinical trial evaluating Metformin, Pioglitazone, and 2 other interventions for Glucose Metabolism Disorders and Diabetes. Completed, enrolled 48 participants across 1 site.

Detailed Summary

Subjects with impaired glucose tolerance will be randomized to receive pioglitazone or metformin for 10 weeks. Measurements of insulin sensitivity, body composition, glucose tolerance, and muscle lipid accumulation will be performed. Adipose tissue and muscle biopsies are performed. The goal of the study is to determine whether the lipotoxiciy of impaired glucose tolerance is ameliorated by pioglitazone.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlucose Metabolism Disorders, Diabetes
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 18, 2005
Enrollment StartJan 1, 2004
Primary CompletionApr 1, 2007
Study CompletionDec 1, 2007
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 21.2 years ago

Interventions

Metformindrug

Pioglitazonedrug

Metformindrug

Pioglitazonedrug

CT scansradiation

To measure changes in adipose tissue volumes

Oral glucose tolerance testprocedure

To detect a change in glucose tolerance